FDMT vs OKTA · rev $37.0K vs P/E 84, rev $2.61B
4D Molecular Therapeutics Inc (FDMT) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported OKTA revenue for 2025-01-31 was $2.61B. Net income was $28.0M. Revenue was up 15.3% from 2024-01-31 to 2025-01-31. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
FDMT currently screens at market cap $518.1M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the FDMT and OKTA stock pages for the full models.
Not investment advice.